Detailed Narrative
Strategic Execution and Growth Drivers
Quest Diagnostics demonstrated strong performance in Q2 FY26, driven by focused execution of its strategy to connect people and providers with innovative testing. The company reported broad clinical demand from physicians, hospitals, and consumers, alongside increased volume from collaborations with Corewell Health and Fresenius Medical Care. Growth was particularly strong in advanced diagnostics across five key clinical areas: advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health, with double-digit revenue increases in several of these segments.
Operational Excellence and Innovation
The company remains on track to achieve 3% in annual cost savings and productivity improvements through its Invigorate program. Investments in AI and automation are enhancing operations, services, and customer experiences. Examples include the installation of the Hologic Genius digital diagnostic system in additional labs for Pap test analysis, front-end specimen processing automation, the launch of IntelliDraw (a web-based tool for specimen collection guidance), and the planned implementation of an AI tool at patient service centers to streamline supply chain management.
Hospital Channel Dynamics
The hospital business, encompassing both reference testing and Co-Lab solutions, saw significant growth, primarily fueled by the Corewell Health relationship. The core reference business experienced mid-single-digit revenue growth, and the Co-Lab business (excluding Corewell) also showed mid-single-digit same-store sales growth. Management noted a strong pipeline for potential collaborations and acquisitions of hospital outreach and independent labs, driven by hospitals seeking partners to improve quality, expand access to innovations, and maximize cost efficiencies.
Consumer Health Channel Performance
The consumer health channel continued to generate robust revenue growth, with questhealth.com showing strong demand for existing wellness panels and new services like thyroid testing. The company is attracting new partners due to its diagnostic innovations, flexible technology integrations, and scale. The total consumer business (direct and indirect), which was approximately $250 million last year, is currently growing at the high end of its projected 20-30% range for 2027.
PAMA Outlook and Advocacy
Management discussed three potential outcomes for PAMA: new rates implemented by CMS based on current data collection (ending July 30), passage of the RESULTS Act, or another delay. Quest Diagnostics is actively advocating for the RESULTS Act, which has strong bipartisan support and proposes a third-party group to collect adjudicated claims, aiming for a more effective and fair determination of market prices for lab data. If passed, the Act would keep rates flat for 2027 and 2028, with new rates in 2029 capped at 5% annual cuts.
Haystack MRD Milestones
Key milestones were achieved for Haystack MRD during the quarter, including New York State approval, which allows commercial efforts to extend to all 50 states. This approval is significant due to New York's rigorous quality criteria. Additionally, Quest Diagnostics became the largest reference lab to extend access to cancer tests like Haystack MRD through Flatiron Health's Onco EMR Molecular Profiling integration platform, with a pilot underway and a broader rollout planned for later this year to Flatiron's 4,700 clinicians.